

## **Post Authorisation Assessments**

## 13 September 2021 Reduction of the shelf life of the finished product as packaged for sale from 5 years to 3 years. 05 June 2019 Change in the safety database of an existing • pharmacovigilance system as described in the DDPS. 20 February 2019 Change in the address of a manufacturer used in the • manufacture of the active substance. 28 January 2019 Minor change in the manufacturing process of an • immediate release solid oral dosage form. 09 November 2018 Change of specifications of a former non • Pharmacopoeial active substance to comply with the Ph. Eur. 25 September 2017 Increase in batch size of the active substance. • Change in the specification parameters and/or limits of a starting material used in the manufacturing process of the active substance. 07 March 2017 Introduction of a new pharmacovigilance system. • 02 December 2016 Tightening of specification limits of the active substance. • Addition of a new in-process test and limits for the active substance. 15 August 2016 Change in the name of a manufacturer of the finished • product including manufacturer responsible for batch release 16 May 2016 Variation to change the marketing authorisation holders • in both Spain and Italy. 13 January 2016 Change of Marketing Authorisation Holder from Novartis • Animal Health UK Ltd to Elanco Europe Ltd. Change in distributor details. 28 April 2014 Grouped variation to change the Qualified Person for • Pharmacovigilance (QPPV) and the QPPV contact details, as well as other changes to the existing pharmacovigilance systems as described in the DDPS. 10 February 2014 Change to the MAH address. • 20 January 2014 Changes to the specification parameters and limits for • the active substances and the finished product. 16 April 2013 Variation to make minor changes to an existing • pharmacovigilance system as described in the DDPS. 31 December 2012 Change in the name of the veterinary medicinal product • in Italy only. 13 September 2011 Change in the specifications of the former non • Pharmacopoeial substance. 09 December 2010 Grouped variation to change the name and gualified • details of the QP for Pharmacovigilance.

## Program Plus Film-coated Tablets 5.75 mg/115 mg

• 30 October 2009	EU Renewal, UK as CMS.
• 19 March 2009	Variation to replace the source of an active component.
• 22 October 2008	Deletion of an obsolete manufacturer.
• 20 October 2008	Change in the name of an active substance manufacturer.
• 01 May 2008	Change to the address of a Distributor.
• 30 June 2006	Change in the name of the veterinary medicinal product in Spain only.
• 08 November 2005	Extension of shelf life.
• 08 November 2005	Change in the name of the veterinary medicinal product in Spain and Austria.
• 19 October 2005	Change of ATC Code.
• 15 February 2005	Tightening of specifications of an active component.
• 15 February 2005	Change of address of an active ingredient manufacturer.
• 15 February 2005	Change of source of an active ingredient.
• 09 November 2004	Changes to an active substance manufacturer.
08 September 2004	Changes to the finished product specification.
• 24 June 2004	Addition of a finished product manufacturer.
• 14 January 2004	EUDE Renewal.
• 20 February 2002	QC Procedure.